Compare Stocks: MDCX, FLNA, IXHL, and CRVO

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CRVO CervoMed	$2.45 -3.2%	$2.77	$2.13 ▼ $10.00	$38.25M	-0.64	213,240 shs	106,887 shs
FLNA Cassava Sciences	$0.70 -3.1%	$0.94	$0.68 ▼ $4.98	$34.72M	-0.69	242,697 shs	445,973 shs
IXHL Incannex Healthcare	$3.45 +4.9%	$3.26	$2.49 ▼ $20.31	$39.36M	6.97	74,223 shs	128,318 shs
MDCX Medicus Pharma	$0.15 -4.5%	$0.29	$0.14 ▼ $3.05	$10.06M	0.12	9.03 million shs	3.08 million shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CRVO CervoMed	-1.56%	-1.17%	-7.33%	-44.03%	-71.41%
FLNA Cassava Sciences	-6.96%	-12.35%	-21.30%	-41.08%	-65.93%
IXHL Incannex Healthcare	+0.92%	+1.54%	+0.30%	-11.80%	-79.97%
MDCX Medicus Pharma	-2.03%	-7.38%	-43.13%	-52.43%	-93.39%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CRVO CervoMed	$2.45 -3.2%	$2.77	$2.13 ▼ $10.00	$38.25M	-0.64	213,240 shs	106,887 shs
FLNA Cassava Sciences	$0.70 -3.1%	$0.94	$0.68 ▼ $4.98	$34.72M	-0.69	242,697 shs	445,973 shs
IXHL Incannex Healthcare	$3.45 +4.9%	$3.26	$2.49 ▼ $20.31	$39.36M	6.97	74,223 shs	128,318 shs
MDCX Medicus Pharma	$0.15 -4.5%	$0.29	$0.14 ▼ $3.05	$10.06M	0.12	9.03 million shs	3.08 million shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CRVO CervoMed	-1.56%	-1.17%	-7.33%	-44.03%	-71.41%
FLNA Cassava Sciences	-6.96%	-12.35%	-21.30%	-41.08%	-65.93%
IXHL Incannex Healthcare	+0.92%	+1.54%	+0.30%	-11.80%	-79.97%
MDCX Medicus Pharma	-2.03%	-7.38%	-43.13%	-52.43%	-93.39%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CRVO CervoMed	2.71	Moderate Buy	$21.00	757.14% Upside
FLNA Cassava Sciences	2.00	Hold	$5.00	617.88% Upside
IXHL Incannex Healthcare	2.00	Hold	$18.00	421.74% Upside
MDCX Medicus Pharma	2.50	Moderate Buy	$9.00	5,817.16% Upside

Current Analyst Ratings Breakdown

Latest MDCX, FLNA, IXHL, and CRVO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/14/2026	MDCX Medicus Pharma	Alliance Global Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
9/3/2026	CRVO CervoMed	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/20/2026	CRVO CervoMed	Roth Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$7.00
8/17/2026	MDCX Medicus Pharma	Alliance Global Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/13/2026	CRVO CervoMed	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/12/2026	CRVO CervoMed	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/3/2026	CRVO CervoMed	Chardan Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
7/31/2026	CRVO CervoMed	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/28/2026	MDCX Medicus Pharma	Alliance Global Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy
7/20/2026	FLNA Cassava Sciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/17/2026	CRVO CervoMed	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)

(Data available from 9/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CRVO CervoMed	$4.01M	9.24	N/A	N/A	$1.97 per share	1.24
FLNA Cassava Sciences	N/A	N/A	N/A	N/A	$1.54 per share	N/A
IXHL Incannex Healthcare	$90K	458.85	N/A	N/A	$2.07 per share	1.67
MDCX Medicus Pharma	N/A	N/A	N/A	N/A	N/A	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CRVO CervoMed	-$26.97M	-$3.22	N/A	N/A	N/A	-672.80%	-156.02%	-128.34%	11/12/2026 (Estimated)
FLNA Cassava Sciences	-$90.97M	-$0.87	N/A	N/A	N/A	N/A	-58.78%	-36.74%	N/A
IXHL Incannex Healthcare	-$46.88M	-$1.55	N/A	N/A	N/A	N/A	-81.01%	-76.11%	9/15/2026 (Estimated)
MDCX Medicus Pharma	-$35.46M	-$2.46	N/A	N/A	N/A	N/A	-3,137.84%	-263.24%	11/13/2026 (Estimated)

Latest MDCX, FLNA, IXHL, and CRVO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
9/15/2026	Q4 2026	IXHL Incannex Healthcare	$0.13	N/A	N/A	N/A	$0.20 million	N/A
8/12/2026	Q2 2026	MDCX Medicus Pharma	-$0.1275	-$0.21	-$0.0825	-$0.21	N/A	N/A
8/7/2026	Q2 2026	CRVO CervoMed	-$0.8640	-$0.64	+$0.2240	-$0.64	$0.05 million	N/A
7/29/2026	Q2 2026	FLNA Cassava Sciences	N/A	-$0.18	N/A	-$0.18	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CRVO CervoMed	N/A	N/A	N/A	N/A	N/A
FLNA Cassava Sciences	N/A	N/A	N/A	N/A	N/A
IXHL Incannex Healthcare	N/A	N/A	N/A	N/A	N/A
MDCX Medicus Pharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CRVO CervoMed	N/A	8.57	8.57
FLNA Cassava Sciences	N/A	2.08	2.08
IXHL Incannex Healthcare	N/A	41.56	41.56
MDCX Medicus Pharma	N/A	1.57	1.57

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CRVO CervoMed	25.15%
FLNA Cassava Sciences	38.05%
IXHL Incannex Healthcare	0.43%
MDCX Medicus Pharma	N/A

Insider Ownership

Company	Insider Ownership
CRVO CervoMed	35.80%
FLNA Cassava Sciences	4.60%
IXHL Incannex Healthcare	1.33%
MDCX Medicus Pharma	8.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CRVO CervoMed	4	15.12 million	9.71 million	Not Optionable
FLNA Cassava Sciences	20	48.31 million	46.09 million	Optionable
IXHL Incannex Healthcare	3	11.97 million	11.81 million	Not Optionable
MDCX Medicus Pharma	N/A	63.18 million	58.06 million	N/A

MDCX, FLNA, IXHL, and CRVO Headlines

Recent News About These Companies

Analysts Are Bullish on These Healthcare Stocks: Genmab (GMAB), Medicus Pharma Ltd (MDCX)

September 15 at 9:13 AM | theglobeandmail.com

Medicus Pharma Ends Standby Equity Purchase Agreement

September 14 at 8:30 AM | tipranks.com

Analysts Offer Insights on Healthcare Companies: Medicus Pharma Ltd (MDCX) and Labcorp Holdings (LH)

September 12 at 6:26 PM | theglobeandmail.com

Medicus Pharma CEO on SkinJect and Pfizer partnership – ICYMI

September 12 at 10:52 AM | proactiveinvestors.com

Medicus Pharma Announces Equity-Based Bonus Share Issuance

September 11, 2026 | tipranks.com

Medicus Pharma identifies 200 µg SkinJect patch as lead development dose after phase 2 study

September 10, 2026 | msn.com

Medicus Pharma reports positive Phase 2 data for SkinJect in skin cancer treatment

September 10, 2026 | proactiveinvestors.com

Medicus Pharma reports positive Phase 2 data for SkinJect in skin cancer treatment

September 10, 2026 | proactiveinvestors.com

Medicus Pharma Ltd. Posts Abridged Phase 2 Clinical Study Report for SkinJect® SKNJCT-003, Advances Gorlin Syndrome Development Plan

September 10, 2026 | quiverquant.comQ

Medicus Pharma Publishes Abridged Final Phase 2 SkinJect® Clinical Study Report (CSR) Results Identifying 200 µg D-MNA Patch as the Lead Development Dose

September 10, 2026 | globenewswire.com

Medicus Surges on New Data

September 8, 2026 | baystreet.ca

Medicus Pharma Prioritises CD228V Oncology Programme in Development Strategy

September 8, 2026 | finance.yahoo.com

Medicus Pharma reorients around new cancer drug candidate, sharpens focus for other programs

September 8, 2026 | proactiveinvestors.com

Medicus Pharma Ltd. Repositions as Precision Oncology-Led Biotech, Prioritizes CD228V, SkinJect and Teverelix Programs

September 8, 2026 | quiverquant.comQ

Medicus Pharma Advances Transformation into a Precision Oncology-Led Biotechnology Company

September 8, 2026 | globenewswire.com

Medicus Posts Wider Loss In Q2 Due To Higher Expenses; Stock Up

September 4, 2026 | rttnews.com

Medicus Pharma Inks Global Licensing Deal with Pfizer Worth Over $1 Billion

September 3, 2026 | benzinga.com

Medicus Pharma advances pipeline during Q2 with key milestones

August 13, 2026 | proactiveinvestors.com

Medicus Pharma advances pipeline during Q2 with key milestones

August 13, 2026 | proactiveinvestors.com

Medicus Pharma Advances SkinJect and Teverelix Amid Financing Gains and Going-Concern Risk

August 12, 2026 | tipranks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

MDCX, FLNA, IXHL, and CRVO Company Descriptions

CervoMed NASDAQ:CRVO

$2.45 -0.08 (-3.16%)

Closing price 04:00 PM Eastern

Extended Trading

$2.48 +0.03 (+1.27%)

As of 07:56 PM Eastern

CervoMed Inc., a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery. The company also develops EIP200 for central nervous system which is in preclinical trials. CervoMed Inc. was founded in 2010 and is headquartered in Boston, Massachusetts.

Cassava Sciences NASDAQ:FLNA

$0.70 -0.02 (-3.10%)

As of 04:00 PM Eastern

Filana Therapeutics Inc is a biotechnology company focused on developing novel, investigational therapies to modulate the filamin A protein for the treatment of central nervous system disorders, such as tuberous sclerosis complex (TSC)-related epilepsy, and other diseases associated with dysregulation or overexpression of filamin A. Its therapeutic product candidate, simufilam, is a proprietary small molecule oral treatment drug being studied for the treatment of TSC-related epilepsy.

Incannex Healthcare NASDAQ:IXHL

$3.45 +0.16 (+4.86%)

Closing price 04:00 PM Eastern

Extended Trading

$3.42 -0.03 (-0.87%)

As of 07:33 PM Eastern

Incannex Healthcare Inc., a clinical stage pharmaceutical development company, engages in the research, development, and sale of medicinal cannabinoid and psychedelic pharmaceutical products and therapies. It develops products for the treatment of obstructive sleep apnoea (OSA), traumatic brain injury (TBI) and concussion, lung inflammation (ARDS, COPD, asthma, bronchitis), rheumatoid arthritis, inflammatory bowel disease, anxiety disorders, addiction disorders, pain, and other indications. The company offers APIRx-1801, an ultrapure tetrahydrocannabinol; APIRx-1802, an ultrapure CBD; and APIRx-1803, an ultrapure cannabigerol. It also develops IHL-42X, which has completed Phase IIb clinical trial for obstructive sleep apnea; Psi-GAD that is in Phase IIa clinical trial for generalized anxiety disorder; MedChew Dronabinol, which has completed Phase Ia clinical trial for nausea and vomiting in chemotherapy; CanChew Plus that has completed Phase IIa clinical trial for irritable bowel syndrome; APIRx-1601, which has completed Phase IIa clinical trial for vitiligo; APIRx-1602 skin that has completed Phase IIa clinical trial for psoriasis; and APIRx-1603, which has completed Phase IIa clinical trial for atopic dermatitis. In addition, its product portfolio includes IHL-675A for inflammatory lung disease, IHL-675A for rheumatoid arthritis, IHL-675A for inflammatory bowel disease, and IHL-216A for traumatic brain injury and concussion, which have completed pre-clinical trials; and MedChew 1401 for pain and spasticity in multiple sclerosis, MedChew GB for post-herpatic neuralgia, MedChew-1502 for Parkinson's disease, MedChew-1503 for dementia, MedChew RL for restless legs syndrome, APIRx 1505 Flotex for chrohn's disease, CanChew RX and SuppoCan (Suppository) for inflammatory bowel disease, CheWell for addiction of cannabis, CanQuit for tobacco smoking cessation, CanQuit O for opioid addiction, APIRx-1701 for glaucoma, suppoCan gastro for IBD, and APIRx-1702 for dry eye syndrome that are in pre-clinical trials. Incannex Healthcare Inc. was incorporated in 2001 and is based in Sydney, Australia.

Medicus Pharma NASDAQ:MDCX

$0.15 -0.01 (-4.52%)

Closing price 04:00 PM Eastern

Extended Trading

$0.15 +0.00 (+0.59%)

As of 07:44 PM Eastern

Medicus Pharma Ltd is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutics assets. Medicus Pharma Ltd is based in Toronto, Ontario.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest MDCX, FLNA, IXHL, and CRVO Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest MDCX, FLNA, IXHL, and CRVO Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

MDCX, FLNA, IXHL, and CRVO Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

MDCX, FLNA, IXHL, and CRVO Company Descriptions

CervoMed NASDAQ:CRVO

Cassava Sciences NASDAQ:FLNA

Incannex Healthcare NASDAQ:IXHL

Medicus Pharma NASDAQ:MDCX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest MDCX, FLNA, IXHL, and CRVO Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest MDCX, FLNA, IXHL, and CRVO Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

MDCX, FLNA, IXHL, and CRVO Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

MDCX, FLNA, IXHL, and CRVO Company Descriptions

CervoMed NASDAQ:CRVO

Cassava Sciences NASDAQ:FLNA

Incannex Healthcare NASDAQ:IXHL

Medicus Pharma NASDAQ:MDCX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools